Camacho-Ortiz Adrián, Gutiérrez-Delgado Eva María, Garcia-Mazcorro Jose F, Mendoza-Olazarán Soraya, Martínez-Meléndez Adrián, Palau-Davila Laura, Baines Simon D, Maldonado-Garza Héctor, Garza-González Elvira
Coordinación de Epidemiología Hospitalaria, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.
Servicio de Infectología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.
PLoS One. 2017 Dec 20;12(12):e0189768. doi: 10.1371/journal.pone.0189768. eCollection 2017.
The aim of this study was to evaluate the impact of fecal donor-unrelated donor mix (FMT-FURM) transplantation as first-line therapy for C. difficile infection (CDI) in intestinal microbiome.
We designed an open, two-arm pilot study with oral vancomycin (250mg every 6 h for 10-14 days) or FMT-FURM as treatments for the first CDI episode in hospitalized adult patients in Hospital Universitario "Dr. Jose Eleuterio Gonzalez". Patients were randomized by a closed envelope method in a 1: 1 ratio to either oral vancomycin or FMT-FURM. CDI resolution was considered when there was a reduction on the Bristol scale of at least 2 points, a reduction of at least 50% in the number of bowel movements, absence of fever, and resolution of abdominal pain (at least two criteria). From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Specimens were cultured to isolate C. difficile, and isolates were characterized by PCR. Susceptibility testing of isolates was performed using the agar dilution method. Fecal samples and FMT-FURM were analyzed by 16S rRNA sequencing.
We included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. However, one of the patients in the vancomycin arm and two patients in the FMT-FURM arm were eliminated. Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, while symptoms resolved in 4/7 patients (57.1%) after the first FMT-FURM dose (P = 0.26) and in 5/7 patients (71.4%) after the second dose (P = 0.55). During the study, no adverse effects attributable to FMT-FURM were observed in patients. Twelve isolates were recovered, most isolates carried tcdB, tcdA, cdtA, and cdtB, with an 18-bp deletion in tcdC. All isolates were resistant to ciprofloxacin and moxifloxacin but susceptible to metronidazole, linezolid, fidaxomicin, and tetracycline. In the FMT-FURM group, the bacterial composition was dominated by Firmicutes, Bacteroidetes, and Proteobacteria at all-time points and the microbiota were remarkably stable over time. The vancomycin group showed a very different pattern of the microbial composition when comparing to the FMT-FURM group over time.
The results of this preliminary study showed that FMT-FURM for initial CDI is associated with specific bacterial communities that do not resemble the donors' sample.
本研究旨在评估粪便供体无关供体混合移植(FMT-FURM)作为艰难梭菌感染(CDI)一线治疗对肠道微生物群的影响。
我们设计了一项开放的双臂试点研究,将口服万古霉素(每6小时250mg,持续10 - 14天)或FMT-FURM作为“何塞·埃莱乌特里奥·冈萨雷斯博士”大学医院住院成年患者首次CDI发作的治疗方法。患者通过封闭信封法以1:1的比例随机分为口服万古霉素组或FMT-FURM组。当布里斯托大便分类法评分至少降低2分、排便次数减少至少50%、无发热且腹痛缓解(至少两项标准)时,视为CDI缓解。在治疗后第0、3和7天从每位患者获取粪便样本。对样本进行培养以分离艰难梭菌,并通过PCR对分离株进行鉴定。使用琼脂稀释法对分离株进行药敏试验。通过16S rRNA测序分析粪便样本和FMT-FURM。
我们纳入了19例患者;万古霉素组10例,FMT-FURM组9例。然而,万古霉素组的1例患者和FMT-FURM组的2例患者被排除。万古霉素组8/9例患者(88.9%)症状缓解,而FMT-FURM组在首次给药后4/7例患者(57.1%)症状缓解(P = 0.26),第二次给药后5/7例患者(71.4%)症状缓解(P = 0.55)。在研究期间,未观察到患者出现归因于FMT-FURM的不良反应。共分离出12株菌株,大多数菌株携带tcdB、tcdA、cdtA和cdtB,tcdC中有一个18bp的缺失。所有分离株对环丙沙星和莫西沙星耐药,但对甲硝唑、利奈唑胺、非达霉素和四环素敏感。在FMT-FURM组,所有时间点细菌组成均以厚壁菌门、拟杆菌门和变形菌门为主,且微生物群随时间显著稳定。与FMT-FURM组相比,万古霉素组随时间推移微生物组成模式差异很大。
这项初步研究结果表明,用于初始CDI的FMT-FURM与特定细菌群落相关,这些群落与供体样本不同。